arylsulfatase a
Recombinant proteinexperimental
Clinical trial activity
6 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2007 (NCT00418561)
Timeline
Indications
Studied for
Mechanism of action
- ArylsulfataseSupplementation
atsA supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- arylsulfatase a
- hgt-1111
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01887938 | Phase 1/Phase 2 (Phase 2) | May 1, 2013 | Shire |
| NCT01510028 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2012 | Shire |
| NCT01303146 | Phase 2 | Oct 1, 2008 | European Leukodystrophy Association, Saint Vincent de Paul Hospital, Paris, Shire, University of Paris, Zymenex |
| NCT00681811 | Phase 2 | Feb 1, 2008 | Shire, University of Copenhagen |
| NCT00633139 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2007 | PhaseOne Trials, Shire |
| NCT00418561 | Phase 1 | Jan 1, 2007 | Shire, University of Copenhagen |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shire | For profit | 6 | 5 | 2 | 2007 |
| University of Copenhagen | Academic/Hospital | 2 | 0 | 2 | 2007 |
| European Leukodystrophy Association | Academic/Hospital | 1 | 0 | 1 | 2008 |
| PhaseOne Trials | For profit | 1 | 0 | 1 | 2007 |
| Saint Vincent de Paul Hospital, Paris | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Paris | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Zymenex | For profit | 1 | 0 | 1 | 2008 |
7 organizations
Page 1 / 1